Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

H. Kamijuku, Y. Nagata, X. Jiang, T. Ichinohe, T. Tashiro, K. Mori, M. Taniguchi, K. Hase, H. Ohno, T. Shimaoka, S. Yonehara, T. Odagiri, M. Tashiro, T. Sata, H. Hasegawa, K. I. Seino

研究成果: Article

79 引用 (Scopus)

抜粋

In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

元の言語English
ページ(範囲)208-218
ページ数11
ジャーナルMucosal Immunology
1
発行部数3
DOI
出版物ステータスPublished - 2008 5 1
外部発表Yes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

フィンガープリント Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Kamijuku, H., Nagata, Y., Jiang, X., Ichinohe, T., Tashiro, T., Mori, K., Taniguchi, M., Hase, K., Ohno, H., Shimaoka, T., Yonehara, S., Odagiri, T., Tashiro, M., Sata, T., Hasegawa, H., & Seino, K. I. (2008). Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunology, 1(3), 208-218. https://doi.org/10.1038/mi.2008.2